Animal models suggest that ALA might modulate blood lipid levels by reducing lipid synthesis while also stimulating lipid metabolism,[1] and may reduce inflammation by reducing the production of inflammatory mediators through inhibition of nuclear factor kappa B (NF-kB). In theory, reductions in inflammation and blood lipids could be protective against cardiovascular disease, but a protective effect hasn’t been consistently found with ALA supplementation. ALA can also be metabolized into other bioactive compounds, such as oxylipins (e.g., eicosanoids), which are a diverse group of lipid mediators that have immune-modulating effects.[2][3]